T-Cell Subset Linked With Survival After Haplo-HCT for Acute Myeloid Leukemia
Researchers sought to determine whether greater Vδ2-positive T-cell recovery would impact mortality for patients with AML who undergo haplo-HCT.
Researchers sought to determine whether greater Vδ2-positive T-cell recovery would impact mortality for patients with AML who undergo haplo-HCT.
59 percent of individuals had organ impairment at one year; breathlessness, cognitive dysfunction, poor HRQoL also common.
Researchers sought to determine whether IM-TMI combined with fludarabine and melphalan would be a feasible conditioning regimen for patients undergoing allo-SCT.
Researchers sought to determine whether a larger dose of decitabine prior to allo-HSCT would improve outcomes in patients with AML.
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Patients with abnormal chest CT had worse overall survival, nonrelapse mortality, pulmonary-related death.
Researchers sought to determine whether changes in physical function during intensive chemotherapy would affect post-transplant survival in older adults with AML.
Researchers sought to determine whether Orca-T could improve relapse and survival outcomes compared with historical controls for patients receiving allo-HSCT.
Researchers sought to determine whether reducing IV crystalloid fluid administration may decrease the risk of respiratory failure in patients receiving haplo-SCT.
Researchers evaluated whether patients who undergo allo-HCT who have a rapid and robust immune recovery have improved clinical outcomes, including OS rates.